Title for MeetingAbstracts
Alphabetical listing of titles
-
Pharmaceuticals vs. psychotherapy for mental health patients: their impact on patient outcomes.
-
Pharmaceuticals, Prescription Plans, and Promoting Progress.
-
Pharmacies and STD/AIDS prevention.
-
Pharmacist Initiated Conversion of Intravenous (IV) to Oral (PO) Therapy for the Treatment of Community-Acquired Pneumonia (CAP) and Evaluation of Barriers to PO Switch.
-
Pharmacists and IVDU: possibilities for prevention.
-
Pharmacists involvement in clinical drug trials sponsored by the AIDS clinical trials group: the role of investigational research pharmacists.
-
Pharmacists' syringe sale practices with injection drug users in Atlanta, Georgia.
-
Pharmaco-economics analysis on a subset of French patients included in the Caesar trial.
-
Pharmaco-economics of Nucleic-acid Amplification Testing (NAT) of Dutch blood donors for HIV.
-
Pharmaco-mechanical applications to HIV infection.
-
Pharmacodynamic (PD) Analysis of Levofloxacin (L) 750 mg IV Daily for Nosocomial Pneumonia.
-
Pharmacodynamic (PD) Comparison and Activity of Moxifloxacin (M), Ciprofloxacin (C), Gatifloxacin (Ga), Gemifloxacin (Ge) and Levofloxacin (L) against Clinical Isolates of Streptococcus pneumoniae (SP) and Staphylococcus aureus (SA).
-
Pharmacodynamic (PD) Comparison of New Fluoroquinolones (FQ) Against Streptococcus pneumoniae (SP) Using Monte Carlo (MC) Analysis.
-
Pharmacodynamic (PD) Comparison of Prolonged and Traditional Infusions of Meropenem (MEM) in Gram- Negative Bacteria.
-
Pharmacodynamic (PD) Driven Dosing of Rifampin (RIF) in a Hollow Fiber System (HFS) Model of Tuberculosis.
-
Pharmacodynamic (PD) Evaluation of Extending the Infusion Time of Meropenem (M) Compared to Standard Imipenem/Cilastatin (I/C) Doses Using Monte Carlo Simulation (MCS).
-
Pharmacodynamic (PD) Evaluation of Extending the Infusion Time of Piperacillin/tazobactam (P/T) Doses Using Monte Carlo Analysis (MC).
-
Pharmacodynamic (PD) Magnitude Comparison of Amphotericin B (AmB) and Liposomal AmB (L-AmB) in a Candidiasis Model.
-
Pharmacodynamic (PD) Modeling of the Selection of grlA Mutants of Methicillin-Resistant Staphylococcus aureus (MRSA) by Garenoxacin (GNX), Gatifloxacin (GAT), and Ciprofloxacin (CIP).
-
Pharmacodynamic (PD) Parameters of Linezolid Associated with Efficacy vs. Streptococcus pneumoniae-Induced Acute Otitis Media (AOM) in Gerbils.
-
Pharmacodynamic (PKPD) Conditions of Emergence and Extinction of Mutant Resistant Streptococcus pneumoniae (MRSp) in Experimental Pneumonia (PNP) Treated with Moxifloxacin (MFX): Limits of the Mutant Selection Window (MSW) Concept.
-
Pharmacodynamic (PKPD) Evaluation of the Efficacy of a Human-Like Treatment with Gatifloxacin (GAT) on Experimental Pneumococcal Pneumonia (PP): Impact of Low Levels of Eesistance.
-
Pharmacodynamic Activity of CS-834, a Novel Oral Carbapenem, against Penicillin-Resistant Streptococcus pneumoniae.
-
Pharmacodynamic Activity of DRF 8417, a Novel Oxazolidinone.
-
Pharmacodynamic Activity of Free Garenoxacin vs. Ciprofloxacin-Resistant Streptococcus pneumoniae (Cip-R SPN) Using an In Vitro Model.
-
Pharmacodynamic Activity of Gatifloxacin on Streptococcus pneumoniae and Staphylococcus aureus in Skin Blister Fluid.
-
Pharmacodynamic Activity of Levofloxacin on Staphylococcus aureus in Skin Blister Fluid.
-
Pharmacodynamic Activity of Newer Quinolones against Streptococcus pneumoniae Containing Specific Mutations in DNA Gyrase and Topoisomerase IV.
-
Pharmacodynamic analysis of efficacy of antifungals in vitro either alone or as a combination.
-
Pharmacodynamic Analysis of In Vitro Efficacy of Combinations of Antifungals against Yeasts.